Evidence map›Paper›PMID 35644124›Full record

ArticleEBioMedicine2022

Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.

Nicolas Chapuis, Nusaibah Ibrahimi, Thibaut Belmondo, Claire Goulvestre, Anne-Emmanuelle Berger, Alice-Andrée Mariaggi, Muriel Andrieu, Camille Chenevier-Gobeaux, Arnaud Bayle, Lydia Campos and 29 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 36 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 8 institutions in 2 countries.

Nicolas ChapuisLaboratory of Hematology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France.
Nusaibah IbrahimiDepartment of Biostatistics and Epidemiology, Gustave Roussy Cancer Center, Villejuif, France; Université Paris-Saclay, INSERM U1018, Gustave Roussy Cancer Center, Villejuif, France.
Thibaut BelmondoLaboratory of Immunology, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Henri Mondor, Créteil, France.
Claire GoulvestreLaboratory of Immunology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France.
Anne-Emmanuelle BergerDepartment of Immunology, University Hospital of Saint Etienne, CIC1408, GIMAP EA3064, Saint Etienne, France.
Alice-Andrée MariaggiUniversité de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France; Assistance Publique-Hôpitaux de Paris, Laboratory of Virology, Cochin hospital, Paris, France.
Muriel AndrieuUniversité de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France.
Camille Chenevier-GobeauxDepartment of automated biological diagnosis, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France.
Arnaud BayleDepartment of Biostatistics and Epidemiology, Gustave Roussy Cancer Center, Villejuif, France; Université Paris-Saclay, INSERM U1018, Gustave Roussy Cancer Center, Villejuif, France; Drug Development Department, Gustave Roussy Cancer Center, Villejuif, France.
Lydia CamposDepartment of Hematology, University Hospital of Saint Etienne, Saint Etienne, France.
Cherifa CheurfaDepartment of Anesthesiology and Intensive care, Assistance Publique-Hôpitaux de Paris, Cochin hospital, Paris, France.
Richard ChocronDepartment of Emergency, Assistance Publique-Hôpitaux de Paris, European Georges Pompidou Hospital, Paris, France; Paris Cardiovascular Research Center (PARCC), Université de Paris, INSERM U970, European Georges Pompidou Hospital, Paris, France.
Jean-Luc DiehlMedical Intensive Care Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital, Paris, France; Université de Paris, Innovative Therapies in Haemostasis, INSERM U1140, Paris France.
Benoît DoumencDepartment of Emergencies, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France.
Jérôme DucheminLaboratory of Hematology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France.
Manon DupratDepartment of Immunology, University Hospital of Saint Etienne, CIC1408, GIMAP EA3064, Saint Etienne, France.
Fabien FrançoisDepartment of Immunology, University Hospital of Saint Etienne, CIC1408, GIMAP EA3064, Saint Etienne, France.
Nicolas GendronUniversité de Paris, Innovative Therapies in Haemostasis, INSERM U1140, Paris France; Department of Emergencies, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France.
Tristant MiraultParis Cardiovascular Research Center (PARCC), Université de Paris, INSERM U970, European Georges Pompidou Hospital, Paris, France.
Frédéric PèneUniversité de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France; Assistance Publique-Hôpitaux de Paris, Medical Intensive Care, Cochin hospital, Paris, France.
Aurélien PhilippeUniversité de Paris, Innovative Therapies in Haemostasis, INSERM U1140, Paris France; Department of Biological Hematology, Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital, Paris France; Laboratory of Hematology and Biosurgical Research (Carpentier Foundation)Assistance Publique-Hôpitaux de Paris, European Georges Pompidou Hospital, Paris, France.
Fanny PommeretMedical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France.
Olivier SanchezUniversité de Paris, Innovative Therapies in Haemostasis, INSERM U1140, Paris France; Department of Pneumology and Intensive Care, Assistance Publique-Hôpitaux de Paris, European Georges Pompidou Hospital, Paris, France.
David M SmadjaUniversité de Paris, Innovative Therapies in Haemostasis, INSERM U1140, Paris France; Department of Biological Hematology, Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital, Paris France.
Tali-Anne SzwebelInternal Medicine Department, Assistance Publique-Hôpitaux de Paris, Cochin hospital, Paris, France.
Aymeric SilvinUniversity Paris-Saclay, INSERM U1015, Gustave Roussy Cancer Center, Villejuif, France.
Florent GinhouxUniversity Paris-Saclay, INSERM U1015, Gustave Roussy Cancer Center, Villejuif, France.
Ludovic LacroixDepartment of Biopathology, Gustave Roussy Cancer Center, Villejuif, France.
Gérôme Jules-ClémentGustave Roussy Cancer Center, Bioinformatics platform, Université Paris-Saclay, INSERM US23, CNRS UMS 3655, Villejuif, France.
Sarobidy RapeteramanaGustave Roussy Cancer Center, Bioinformatics platform, Université Paris-Saclay, INSERM US23, CNRS UMS 3655, Villejuif, France.
Colette MavierThermofisher immunodiagnostics, Dardilly, France.
Laura StellerThermo Fisher Scientific ImmunoDiagnostics, Phadia GmbH, Freiburg, Germany.
Barbara PerniconiCerbaXpert Alliance, Saint Ouen L'Aumone, France.
Fabrice AndréMedical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France.
Damien DrubayDepartment of Biostatistics and Epidemiology, Gustave Roussy Cancer Center, Villejuif, France; Université Paris-Saclay, INSERM U1018, Gustave Roussy Cancer Center, Villejuif, France.
Michaela FontenayLaboratory of Hematology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France; Laboratory of Immunology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France.
Sophie HüeLaboratory of Immunology, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Henri Mondor, Créteil, France.
Stéphane PaulDepartment of Immunology, University Hospital of Saint Etienne, CIC1408, GIMAP EA3064, Saint Etienne, France.
Eric SolaryUniversité Paris-Saclay, INSERM U1287, Gustave Roussy Cancer Center, 114 rue Edouard Vaillant, Villejuif 94805, France; Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France. Electronic address: eric.solary@gustaveroussy.fr.
Inserm · FRCentre National de la Recherche Scientifique · FRHôpital Cochin · FRCentre Hospitalier Universitaire de Saint-Étienne · FRInstitut Gustave Roussy · FRCentre Hospitalier Universitaire Henri-Mondor · FRThermo Fisher Scientific (Germany) · DEVirbac (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere COVID-19 is associated with a high circulating level of calprotectin, the S100A8/S100A9 alarmin heterodimer. Baseline calprotectin amount measured in peripheral blood at diagnosis correlates with disease severity. The optimal use of this biomarker along COVID-19 course remains to be delineated.

methodsWe focused on patients with a WHO-defined moderate COVID-19 requiring hospitalization in a medical ward. We collected plasma and serum from three independent cohorts (N = 626 patients) and measured calprotectin amount at admission. We performed longitudinal measures of calprotectin in 457 of these patients (1461 samples) and used a joint latent class mixture model in which classes were defined by age, body mass index and comorbidities to identify calprotectin trajectories predicting the risk of transfer into an intensive care unit or death.

findingsAfter adjustment for age, sex, body mass index and comorbidities, the predictive value of baseline calprotectin in patients with moderate COVID19 could be refined by serial monitoring of the biomarker. We discriminated three calprotectin trajectories associated with low, moderate, and high risk of poor outcome, and we designed an algorithm available as online software (https://calpla.gustaveroussy.fr:8443/) to monitor the probability of a poor outcome in individual patients with moderate COVID-19.

interpretationThese results emphasize the clinical interest of serial monitoring of calprotectin amount in the peripheral blood to anticipate the risk of poor outcomes in patients with moderate COVID-19 hospitalized in a standard care unit.

fundingThe study received support (research grants) from ThermoFisher immunodiagnostics (France) and Gustave Roussy Foundation.

Indexed as

COVID-19Leukocyte L1 Antigen ComplexBiomarkersHumansSeverity of Illness IndexBiomarkersLeukocyte L1 Antigen ComplexBiomarkerCalprotectinCOVID-19DynamicsS100A8/A9Serial measurement

Identifiers

PMID35644124
PMCPMC9132728
OpenAlexW4281562250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.